91Ï㽶ÊÓƵ

91Ï㽶ÊÓƵ today announced it has completed expansion of its clinical supply facility in Schorndorf, Germany.

91Ï㽶ÊÓƵ will provide process development and cGMP manufacturing of Siren Biotechnology’s AAV vector-based therapeutic candidates for use in clinical trials.

The 2023 Corporate Responsibility Report highlights progress across every pillar of 91Ï㽶ÊÓƵ’s corporate responsibility strategy – People, Environment, and Community.

91Ï㽶ÊÓƵ and Novo Holdings have entered into a merger agreement under which Novo Holdings will acquire 91Ï㽶ÊÓƵ in an all-cash transaction that values 91Ï㽶ÊÓƵ at $16.5 billion on an enterprise value basis.

These upgrades, including the addition of capacity for both development and commercial spray drying, now position 91Ï㽶ÊÓƵ as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.

The company also committed to engaging with its suppliers such that 70% of their emissions will have reduction goals aligned with science-based targets by the end of fiscal 2028.

Mr. McErlane will lead all of 91Ï㽶ÊÓƵ’s Biologics businesses and global service offerings – including development, drug substance manufacturing, drug product fill-and-finish, cell and gene therapy, and analytical services.

She will be responsible for leading 91Ï㽶ÊÓƵ’s global human resources strategy, including talent acquisition, leadership development, diversity and inclusion, compensation and benefits, HR operations and technology, and performance management.

Mr. Masanovich will have responsibility for all aspects of 91Ï㽶ÊÓƵ’s global financial operations, including financial planning and analysis, controllership, public reporting and investor relations, capital markets activities, bill payment and collection, tax, and treasury.